LexaGene to Advance Rapid Pathogen Detection

LexaGene Pathogen Detection

The Back Story

LexaGene is poised to provide easy pathogen detection for food safety, water quality, veterinary diagnostics, and other pathogen detection applications. This includes viruses such as COVID-19. The biotechnology company selected Boston Engineering to transform its concept into the industry’s first fully automated, open-access pathogen detection platform.

The Approach

Product development for LexaGene’s quantitative polymerase chain reaction (qPCR) system includes:

  • Industrial design and human factorsLexaGene disposables, vet clinic
  • Microfluidic concept research and development
  • Disposable sample and preparation cartridge development
  • Chilled fluid storage, thermal management
  • Multi-threaded, parallel software architecture
  • Temperature proportional-integral-derivative (PID) controller design
  • Thermal simulation, materials analysis
  • Alpha prototype development

 

Addressing COVID-19 and Commercialization

The full Alpha prototype includes the following features:

  • Deliver many test results in approximately one hour, which is exponentially faster than waiting 1-5 days for standard food safety test results
  • Provide ease of operation so that users don’t need technical training to run accurate tests
  • Accelerate testing by processing multiple samples concurrently while also analyzing each sample for different types of pathogens
  • Tailor testing parameters via user-configurable, parameterized scripting and configurable pathogen detection assays
  • Support variable sample input volumes to reduce the requirements to run effective tests

COVID-19 testing takes days to complete because patient samples need to be shipped to laboratories and are then processed manually. LexaGene is addressing this problem by developing the first diagnostic analyzer for points-of-need environments – including clinics, hospitals, and airports. The company’s genetic analyzer can detect new pathogens and other molecular markers in hours instead of days. And, and each test screens for up to 27 pathogens at once, thereby generating usable data for healthcare providers.

For more information, please visit LexaGene Holdings Inc. online (OTCQB:LXXGF) (TSX-V:LXG).

 

Medical Device Development

Learn more about our ISO 13485:2016 product development capabilities.

Read More

Biomedical Development

See how we innovate for biotherapeutics and diagnostics companies.

Read More

COVID-19 Case Studies

 See how medical companies are using innovation and determination to address the pandemic. 

Read More